Immunosuppressive drugs in organ transplantation to prevent allograft rejection: Mode of action and side effects

Elisa Claeys, Kurt Vermeire*
KU Leuven Department of Microbiology, Immunology and Transplantation, Rega Institute, Laboratory of Virology and Chemotherapy, B-3000 Leuven, Belgium

ABSTRACT

Organ transplantation is a life-saving therapeutic intervention that contributes to a better quality of life in patients with end-stage organ failure. Drastically improved outcome after organ transplantation occurred with the discovery and use of immunosuppressive drugs to prevent or treat allograft rejection. Development of several immunosuppressive agents offers the option for a multidrug approach with non-overlapping toxicities. Still, the side effects of these agents can be severe, resulting in a shorter life expectancy for transplant patients compared to the general population. Therefore, the development of new immunosuppressive therapies that promote immune tolerance without the side effects observed today is needed. In this review, we will discuss the mechanism of allograft rejection as well as the mode of action and side effects of currently used immunosuppressive agents.

Introduction

Organ transplantation is the treatment of choice for patients with end-stage organ failure, thereby increasing patient survival and improving quality of life. In the first two decades after introduction of organ transplantation in the clinic, the main obstacle to success had been acute allograft rejection, a common cause of early graft loss. Significant progress has been made with the discovery and use of immunosuppressive drugs. With the current immunosuppressive drugs, one-year graft survival now exceeds 90% in most centers. Unfortunately, long-term graft survival still lags behind.

A multidrug approach involving medications with different mechanisms of action and non-overlapping toxicity profiles is commonly used to lower the doses of individual drugs in order to reduce toxicity. There are three phases in immunosuppression: induction, maintenance and treatment of rejection. The induction phase involves the use of high-intensity immunosuppression immediately after transplantation, when the risk of rejection is highest. Induction therapy can involve the use of antibodies or higher doses of medications used for maintenance therapy. The standard triple medication regimen consists of the combination of a calcineurin inhibitor, an antiproliferative agent and a corticosteroid. As immunosuppressed patients are susceptible to opportunistic infections, the treatment regimen is often supplemented with...
antimicrobial, antiviral and antifungal agents. The side effects of immunosuppressive drugs can be severe (including an increased risk of cancer and infections), which is one of the reasons that life expectancy of transplant patients still falls short of that of the general population. Therefore, there is a need for newer drugs that promote immune tolerance without the side effects observed with current immunosuppressive agents.

Two distinct manners exist by which transplantation tolerance can be achieved: central and peripheral tolerance. Central tolerance includes the deletion or inactivation of alloreactive T cells at the time of development in the thymus. Peripheral tolerance, on the other hand, involves the deletion, inactivation or regulation of reactive immune cells after they have reached the circulation. In other words, the term 'peripheral tolerance' is applied to approaches that aim to anergize, suppress or delete alloreactive peripheral T cells. A promising approach of peripheral tolerance is the use of regulatory T (Treg) cells in a transplant setting.

**Allograft rejection**

Rejection of the transplanted organ involves many components of the immune system including CD4+ T cells, CD8+ T cells, B cells, cytokines and antibodies. T cell-mediated alloimmune responses occur through recognition of alloantigens presented by donor and recipient antigen-presenting dendritic cells to recipient CD4+ and CD8+ T cells. Alloreactive CD4+ T cells can be induced by direct recognition of allogeneic major histocompatibility complex (MHC) class II molecules or by indirect recognition of peptides of allogeneic MHC molecules presented by self-MHC class II molecules (Figure 1). A third mechanism of allorecognition is the semi-direct pathway in which recipient antigen presenting cells (APCs) can acquire intact allogeneic MHC-peptide complexes through MHC transfer. Either way, alloreactive T cells get activated by a combination of alloantigen recognition through the T cell receptor/CD3 complex and a co-stimulatory signal, often an interaction between CD28 on the T cell and CD80 or CD86 on the APC. This results in interleukin (IL)-2 secretion and T cell proliferation.

Several subsets of CD4+ T helper (Th) cells exist and are implicated in allograft rejection. Th1 cells contribute to transplant rejection via different mechanisms: (1) they produce IL-2, which promotes the proliferation of alloreactive cytotoxic CD8+ T cells, (2) they activate B cells to produce alloreactive antibodies and (3) they can directly cause allograft damage through Fas/Fas ligand-mediated cytotoxicity. Although several studies have shown that Th2 cells are involved in transplant rejection, it was suggested that Th2 cells can delay and even prevent rejection due to the production of IL-4 and IL-10, two cytokines that are able to inhibit Th1 responses. However, there is mounting evidence that Th2 cytokines promote graft rejection by activating eosinophils. Th17 cells also seem to be involved in transplant rejection through production of IL-17A and neutrophil recruitment. Concerning Treg therapy in transplantation, it was shown that Th1 and Th2 cells are susceptible to suppression by Treg cells, but it is not clear whether Treg cells are capable of suppressing Th17 cells as conflicting data were published.

![Figure 1. Mechanism of direct and indirect allograft recognition.](image-url)
about this\textsuperscript{17, 18}. Little is known about the involvement of Th9 and Th22 in allograft rejection. There is a link between IL-9 as well as IL-22 and transplant rejection, but many other cell types may secrete these cytokines as well\textsuperscript{11}. Finally, another T cell subset implicated in transplant rejection worth mentioning include T follicular helper cells. These cells are known to provide help to B cells for alloantibody production in transplant recipients\textsuperscript{19}.

### Immunosuppressive drugs and their side effects

Suppression of the immune response against the transplanted tissue can be achieved through the administration of immunosuppressive drugs. Several classes of these drugs exist with different mechanisms of action and various side effects. An overview of these agents is given in Table 1.

#### Table 1. Immunosuppressive drugs and their mechanisms of action and side effects.

<table>
<thead>
<tr>
<th>Immunosuppressive drug</th>
<th>Mechanism of action</th>
<th>Side effects</th>
</tr>
</thead>
<tbody>
<tr>
<td>Antithymocyte globulin</td>
<td>Blocks T cell membrane proteins, resulting in T cell depletion</td>
<td>Cytokine-release syndrome</td>
</tr>
<tr>
<td></td>
<td></td>
<td>Lymphopenia</td>
</tr>
<tr>
<td></td>
<td></td>
<td>Increased risk of post-transplant lymphoma</td>
</tr>
<tr>
<td>Alemtuzumab (CAMPATH-1H)</td>
<td>Directed against CD52, thereby depleting T cells, B cells, NK cells and monocytes</td>
<td>Cytokine-release syndrome</td>
</tr>
<tr>
<td></td>
<td></td>
<td>Lymphopenia</td>
</tr>
<tr>
<td></td>
<td></td>
<td>Autoimmune phenomena</td>
</tr>
<tr>
<td>Rituximab</td>
<td>Directed against CD20, inducing B cell depletion</td>
<td>Infusion-related reactions</td>
</tr>
<tr>
<td>Basiliximab</td>
<td>Directed against CD25, thereby inhibiting IL-2-induced T cell proliferation</td>
<td>Hypersensitivity reactions</td>
</tr>
<tr>
<td>Daclizumab</td>
<td>Directed against CD25, thereby inhibiting IL-2-induced T cell proliferation</td>
<td>Withdrawn from market due to reports of serious inflammatory brain disorders</td>
</tr>
<tr>
<td>Belatacept</td>
<td>Blocks co-stimulation by binding to CD80 and CD86 receptors on APCs and thereby prevents binding to CD28 on the T cell</td>
<td>Increased risk of post-transplant lymphoproliferative disease? Bone marrow suppression Hypertension Dyslipidemia</td>
</tr>
<tr>
<td>Azathioprine</td>
<td>Inhibits purine synthesis, resulting in reduced T cell proliferation</td>
<td>Leukopenia and thrombocytopenia</td>
</tr>
<tr>
<td></td>
<td></td>
<td>Nausea and vomiting</td>
</tr>
<tr>
<td></td>
<td></td>
<td>Hepatotoxicity</td>
</tr>
<tr>
<td></td>
<td></td>
<td>Increased incidence of malignancies</td>
</tr>
<tr>
<td>Mycophenolate mofetil</td>
<td>Inhibits inosine monophosphate dehydrogenase, resulting in inhibition of T and B cell proliferation</td>
<td>Neutropenia</td>
</tr>
<tr>
<td></td>
<td></td>
<td>Anorexia, abdominal pain, gastritis and diarrhea</td>
</tr>
<tr>
<td></td>
<td></td>
<td>Opportunistic infections</td>
</tr>
<tr>
<td></td>
<td></td>
<td>Teratogenic effects</td>
</tr>
<tr>
<td>Cyclosporine</td>
<td>Binds to cyclophilin and forms a complex that inhibits calcineurin, leading to reduced cytokine production and decreased T cell proliferation</td>
<td>Acute and chronic nephrotoxicity</td>
</tr>
<tr>
<td></td>
<td></td>
<td>Hypomagnesemia and hyperkalem</td>
</tr>
<tr>
<td></td>
<td></td>
<td>Neurotoxicity</td>
</tr>
<tr>
<td></td>
<td></td>
<td>Increased risk of malignancies</td>
</tr>
<tr>
<td></td>
<td></td>
<td>Increased risk of diabetes</td>
</tr>
<tr>
<td>Tacrolimus</td>
<td>Binds to FK506-binding protein 12 and forms a complex that inhibits calcineurin, leading to reduced cytokine production and decreased T cell proliferation</td>
<td>Similar to cyclosporine except: Lower incidence of hyperlipidemia, hypertension, hirsutism and gingival hyperplasia</td>
</tr>
<tr>
<td></td>
<td></td>
<td>Higher incidence of diabetes and neurotoxicity</td>
</tr>
<tr>
<td>Sirolimus and everolimus</td>
<td>Bind to FK506-binding protein 12, thereby inhibiting mTOR, resulting in decreased cytokine-driven T cell proliferation</td>
<td>Delayed wound healing</td>
</tr>
<tr>
<td></td>
<td></td>
<td>Leukopenia and thrombocytopenia</td>
</tr>
<tr>
<td></td>
<td></td>
<td>Increased risk of infections</td>
</tr>
<tr>
<td></td>
<td></td>
<td>Anaphylaxis and hypersensitivity reactions</td>
</tr>
<tr>
<td></td>
<td></td>
<td>Hyperlipidemia</td>
</tr>
<tr>
<td></td>
<td></td>
<td>Life-threatening pneumonitis</td>
</tr>
<tr>
<td></td>
<td></td>
<td>Mouth ulcers and increased mortality with sirolimus</td>
</tr>
<tr>
<td>Corticosteroids</td>
<td>Reduce the number of circulating lymphocytes, monocytes and eosinophils and inhibit cytokine production</td>
<td>Impaired wound healing</td>
</tr>
<tr>
<td></td>
<td></td>
<td>Opportunistic infections</td>
</tr>
<tr>
<td></td>
<td></td>
<td>Psychiatric and sleep disturbances</td>
</tr>
<tr>
<td></td>
<td></td>
<td>Mood changes</td>
</tr>
<tr>
<td></td>
<td></td>
<td>Cushing's syndrome</td>
</tr>
<tr>
<td></td>
<td></td>
<td>Hyperglycemia</td>
</tr>
<tr>
<td></td>
<td></td>
<td>Hypertension</td>
</tr>
<tr>
<td></td>
<td></td>
<td>Dyslipidemia</td>
</tr>
<tr>
<td></td>
<td></td>
<td>Osteoporosis</td>
</tr>
<tr>
<td></td>
<td></td>
<td>Cardiovascular side effects</td>
</tr>
</tbody>
</table>
Depleting antibodies: antithymocyte globulin, Alemtuzumab and Rituximab

Antithymocyte globulins (ATGs) are polyclonal immunoglobulins from horses or rabbits that are immunized with human thymocytes. They recognize several T cell membrane proteins, which results in inactivation, depletion and modulation of the homing and cytotoxic activities of T cells. It also interferes with the function of B cells, dendritic cells and natural killer T cells. It was even suggested that ATG would induce Treg cells. Rabbit ATG is preferred over horse ATG because of better results in reversing and preventing rejection and improved tolerability. Rabbit ATG also induces a profound, long-lasting lymphopenia and an increased risk of post-transplant lymphoma was observed.

Alemtuzumab (also known as CAMPATH-1H) is a humanized rat IgG1 monoclonal antibody directed against the CD52 cell surface antigen, expressed on T cells, B cells, natural killer cells and monocytes. It results in depletion of these cell populations and is used for induction and treatment of steroid-resistant rejection in solid organ transplants. Like ATG, Alemtuzumab was suggested to induce Treg cells. Treatment with Alemtuzumab results in profound, long-lasting lymphopenia. Cytokine-release syndrome is also observed with Alemtuzumab, although much milder compared to ATG. Alemtuzumab was associated with autoimmune phenomena such as thyroid disease, hemolytic anemia and thrombocytopenia in patients with multiple sclerosis.

Rituximab is a monoclonal antibody against CD20, which is present on almost all B cells except for plasma cells. It is under study for application in antibody-mediated rejection, ABO-incompatible transplantations and desensitization of human leukocyte antigen-sensitive patients. Disappointing results came from a study that evaluated Rituximab as an induction agent. Side effects include infusion-related reactions.

Nondepleting antibodies: Basiliximab and Daclizumab

Basiliximab is a chimeric human/mouse monoclonal antibody directed against the IL-2 receptor α-chain also known as CD25, which is expressed on activated T cells. It prevents IL-2 from binding to its receptor and thereby inhibits T cell proliferation and differentiation, but does not cause depletion of T cells. Basiliximab can be used for induction therapy in prophylaxis of acute rejection. ATG is mostly used for high-risk patients, whereas Basiliximab is a good option for low-risk patients. Few adverse effects are reported and some hypersensitivity reactions have been described.

Daclizumab is a humanized monoclonal antibody that also targets CD25 and was indicated as induction therapy. However, Daclizumab was also used for the treatment of multiple sclerosis, but was withdrawn from the global market in 2018 after worldwide reports of serious inflammatory brain disorders.

Belatacept

Belatacept is a fusion protein composed of the modified extracellular domain of cytotoxic T lymphocyte-associated protein 4 (CTLA-4) and the Fc domain of human immunoglobulin IgG1. It blocks co-stimulation by binding to CD80 and CD86 receptors on APCs and thereby prevents binding to CD28 on the T cell. Belatacept is used in combination with other immunosuppressive drugs as maintenance therapy. Treatment with Belatacept holds an increased risk for the development of post-transplant lymphoproliferative disease. When treated with Belatacept, patients who are Epstein-Barr virus-negative are at higher risk of developing post-transplant lymphoproliferative disease. Therefore, Belatacept should only be used in patients who are Epstein-Barr virus-positive. These observations about post-transplant lymphoproliferative disease with treatment of Belatacept were however not confirmed in a later study. Other reported adverse effects include bone marrow suppression, hypertension and dyslipidemia.

Antiproliferative or antimetabolite agents: azathioprine and mycophenolate mofetil

Azathioprine inhibits purine synthesis and is a prodrug that releases 6-mercaptopurine, which is incorporated into the cellular DNA, thereby halting replication and resulting in reduced T cell proliferation. Azathioprine is used as maintenance therapy. The main adverse effects of azathioprine are hemato logical including leukopenia and thrombocytopenia, and gastrointestinal with complaints of nausea and vomiting. Hepatotoxicity and increased incidence of malignancies have also been observed.

Mycophenolate mofetil (MMF) is a prodrug that is hydrolyzed to the active immunosuppressant mycophenolic acid. It inhibits inosine monophosphate dehydrogenase, thereby causing inhibition of the de novo purine nucleotide synthesis. As T and B cells lack a key enzyme for the salvage pathway of guanine nucleotides, they almost exclusively rely on this de novo purine nucleotide synthesis pathway. Therefore, MMF results in inhibition of T and B cell proliferation by blocking DNA synthesis, making it more selective than azathioprine. Because of this reason, MMF would be less hepatotoxic and is not associated with...
malignancies. MMF would also decrease the recruitment of lymphocytes and monocytes into inflammatory tissue and it would upregulate CD70 expression on lymphocytes, which mediates anergy. Like azathioprine, MMF is used as part of maintenance therapy and the adverse effects of MMF can be categorized as hematological including neutropenia, and gastrointestinal including anorexia, abdominal pain, gastritis and diarrhea. Opportunistic infections are also observed in patients on this drug. MMF has teratogenic effects as it increases the risk of pregnancy in discontinuation of treatment.

Calcineurin inhibitors: cyclosporine and tacrolimus

Cyclosporine is produced by the fungus Beauveria nivea and works by binding to cyclophilin. This complex inhibits the activity of calcineurin, a calcium-dependent phosphatase, and this results in reduced activation of nuclear factor of activated T cells (NFAT), leading to decreased cytokine production (including IL-2) and diminished proliferation of T cells. Calcineurin inhibitors are the cornerstones of maintenance immunosuppression, but a major disadvantage is their inhibitory effect on Treg cells given the dependence of these cells on IL-2 and their need for nuclear NFAT to express FOXP3 efficiently.

Tacrolimus (FK506) is derived from the bacterium Streptomyces tsukubaensis and binds to FK506-binding protein 12 to form a complex that inhibits calcineurin. Inhibition of calcineurin occurs with greater potency compared to cyclosporine. Adverse effects of calcineurin inhibitors include acute and chronic nephrotoxicity, electrolyte abnormalities such as hypomagnesemia and hyperkalemia, neurotoxicity, increased risk of malignancy and diabetes or hyperglycemia. Tacrolimus has lower incidence of hyperlipidemia, hypertension and cosmetic problems such as hirsutism and gingival hyperplasia, but is more likely than cyclosporine to induce diabetes and neurotoxicity. Tacrolimus is preferred when renal function is reduced. Tacrolimus is also used in management of acute rejection.

Mammalian target of rapamycin inhibitors: sirolimus and everolimus

Sirolimus (also known as rapamycin) is derived from the bacterium Streptomyces hygroscopicus and binds to FK506-binding protein 12. In contrast to tacrolimus, this complex does not bind to calcineurin, but instead inhibits mammalian target of rapamycin (mTOR), a serine/threonine kinase that is important in the regulation of cell growth and proliferation. This results in inhibition of cytokine-driven T cell proliferation. It was also suggested that sirolimus inhibits immunoglobulin synthesis by B cells, antibody-dependent cellular cytotoxicity as well as natural killer cell activity. mTOR inhibitors are used as maintenance therapy and since delayed wound healing due to impaired response of fibroblasts to fibroblast growth factor is a major concern with these drugs, it is generally recommended not to start mTOR inhibitors immediately after transplant surgery. mTOR inhibitors are often used in patients experiencing calcineurin inhibitor-mediated nephrotoxicity.

Everolimus is a derivative of sirolimus with improved oral bioavailability and shares its mechanism of action. Both sirolimus and everolimus are associated with an increased risk of infections, hyperlipidemia as well as leukopenia and thrombocytopenia. Anaphylaxis and hypersensitivity reactions have been observed too. mTOR inhibitors are less nephrotoxic and diabetogenic compared to calcineurin inhibitors, but they can cause life-threatening pneumonitis. In addition, sirolimus was associated with increased mortality. However, mTOR inhibitors appear to have some anti-tumor properties, so they are the treatment of choice in transplant patients in whom cutaneous squamous-cell carcinomas develop or in whom post-transplant Kaposi’s sarcoma develops.

Corticosteroids

Corticosteroids exhibit anti-inflammatory and immunosuppressive activity through three mechanisms: direct genomic effects, indirect genomic effects and nongenomic mechanisms. Direct genomic effects occur when corticosteroids together with their receptor move to the nucleus and directly affect transcription. This, for example, induces annexin I and mitogen-activated protein kinase, resulting in inhibition of prostaglandin synthesis and in reduced inflammation. Indirect genomic effects take place when corticosteroids and their receptors interact with other transcription factors. This allows other responses to include annexin I and mitogen-activated protein kinase. Inhibition of pro-inflammatory gene expression is also observed. Nongenomic effects occur very rapidly and include the activation of endothelial nitric oxide synthase, which appears to protect against ischemia and reperfusion-induced injury in mice. The net result of these pathways is a dramatic reduction in circulating lymphocytes, monocytes and eosinophils due to redistribution, inhibition of cytokines and induction of...
apoptosis68. Corticosteroids are used both for induction and maintenance therapy, but long-term use is associated with several side effects including opportunistic infections, Cushing’s syndrome, psychiatric and sleep disturbances, mood changes, hyperglycemia, hypertension, dyslipidemia, impaired wound healing and osteoporosis. Corticosteroids also play a role in cardiovascular events after successful transplantation69.

Conclusions

The outcome of organ transplantation has majorly improved since the development of immunosuppressive drugs. Still, the side effects of these drugs can be severe, resulting in a shorter life expectancy for transplant patients compared to the general population. Thus, the development of new therapies that can induce immune tolerance in combination with no or limited side effects is needed. Fortunately, several novel strategies of immune tolerance induction are getting explored. For example, therapy based on Treg cells or chimeric antigen receptor (CAR) Treg cells is very promising in the transplantation field70. Additionally, novel immunosuppressive biologics (e.g. anti-IL-6)71 or kinase inhibitors (e.g. anti-JAK3)72 are emerging to prevent or treat allograft rejection after transplantation.

Acknowledgements

This work was partly supported by the KU Leuven grant no. PF/10/018. The figure was created using BioRender.

References

31. Bloom DD, Chang Z, Rechner JH, et al. CD4+ CD25+ FOXP3+ regulatory T cells increase de novo in kidney transplant patients after...


Claeys E, Vermeire K. Immunosuppressive drugs in organ transplantation to prevent allograft rejection: Mode of action and side effects. J Immunological Sci. (2019); 3(4): 14-21

